Avicena Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors
October 10 2007 - 4:52PM
PR Newswire (US)
PALO ALTO, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Avicena Group,
Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a late-stage biotechnology
company that develops central nervous system therapeutics for
neurodegenerative disorders, announced today the appointment of its
C.E.O., Belinda Tsao-Nivaggioli, Ph.D., to the additional role of
Chairman of the Company's Board of the Directors. Dr. Tsao-
Nivaggioli succeeds Nasser Menhall, who recently resigned from the
Board to focus his time on other business ventures. "I want to take
this opportunity to thank Nasser for his many contributions and his
invaluable leadership over many years and I wish him best of luck
in his new ventures," stated Dr. Tsao-Nivaggioli. "I appreciate the
Board of Directors' vote of confidence and I continue to be proud
to be associated with this organization and its people. I look
forward to leading this Company and to further leveraging our
cellular energy technology to develop and commercialize
pharmaceutical and dermaceutical products." Prior to her current
roles of CEO and Chairman, Dr. Tsao-Nivaggioli was Avicena's chief
operating officer from 2002 to 2004. During her tenure with the
Company, Dr. Tsao-Nivaggioli has expanded its intellectual property
portfolio and built a substantial pipeline of pharmaceutical
products, including drug candidates for the treatment of
neurological disorders such as ALS, Huntington's and Parkinson's
Disease. Dr. Tsao-Nivaggioli is also credited with solidifying the
Company's relationship with the National Institutes of Health (NIH)
as well as developing the Company's dermaceutical programs. ABOUT
AVICENA Avicena Group, Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) is a
Palo Alto, California based late-stage biotechnology company that
develops central nervous system therapeutics for neurodegenerative
disorders. The Company's core technologies, supported by a robust
IP portfolio, have broad applications in both pharmaceuticals and
dermaceuticals. Avicena's pharmaceutical program centers on rare
neurological disorders (orphan diseases). Near term, the Company
plans to initiate a confirmatory Phase III trial in ALS and a Phase
III trial in Huntington's disease to accompany the ongoing NIH
Phase III trail in Parkinson's disease. Avicena's science is well
established and its products are safe and well tolerated. Unlike
traditional biotechnology companies, Avicena's clinical programs
are largely funded by government and non-profit organizations.
Avicena presently derives revenue from the sale of proprietary
dermaceutical ingredients to skin care manufacturers. Contact: The
Ruth Group (on behalf of Avicena Group) Sara Ephraim (investors)
(646) 536-7002 Janine McCargo / Jason Rando (media) (646) 536-7033
/ 7025 or DATASOURCE: Avicena Group, Inc. CONTACT: investors, Sara
Ephraim, +1-646-536-7002, , or media, Janine McCargo,
+1-646-536-7033, , or Jason Rando, +1-646-536-7025, , all of The
Ruth Group for Avicena Group Web site: http://www.avicenagroup.com/
Copyright